Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kestra Medical TechnologiesKMTS -1.70%12 3-Year FCF Growth Rate is 20.40% as of Apr. 2026. GuruFocus rates KMTS with a GF Score™ of 12/100. The stock has 6 warning signs investors should review. Among 584 Medical Devices & Instruments companies, Kestra Medical Technologies ranks better than 52.74% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 20.40% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -14.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 6 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Kestra Medical Technologies was 20.40% per year. The lowest was -40.60% per year. And the median was -39.40% per year.
Kestra Medical Technologies (NAS:KMTS) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Kestra Medical Technologies 3-Year FCF Growth Rate Related Terms
KMTS vs AZTA, BLFS, LMAT: 3-Year FCF Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kestra Medical Technologies 3-Year FCF Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Kestra Medical Technologies's 3-Year FCF Growth Rate falls into.
Kestra Medical Technologies 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 20.40% mean?
Kestra Medical Technologies (KMTS) has a 3-Year FCF Growth Rate of 20.40% as of Apr. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Kestra Medical Technologies and its competitors. According to the industry distribution chart, Kestra Medical Technologies ranks #276 out of 584 companies in the Medical Devices & Instruments industry, placing it in the top 47.3%.
Is Kestra Medical Technologies' 3-Year FCF Growth Rate too high?
Kestra Medical Technologies' current 3-Year FCF Growth Rate is 20.40%. The Medical Devices & Instruments industry median 3-Year FCF Growth Rate is 18.00. Kestra Medical Technologies' value of 20.40% is 13.3% above this industry median. Based on the distribution chart, Kestra Medical Technologies ranks #276 out of 584 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Kestra Medical Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' 3-Year FCF Growth Rate compare to AZTA and BLFS?
According to the Medical Devices & Instruments industry distribution chart, Kestra Medical Technologies ranks #276 out of 584 companies for 3-Year FCF Growth Rate. This puts Kestra Medical Technologies in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 18.00. Kestra Medical Technologies' value of 20.40% is 13.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Devices & Instruments company?
The median 3-Year FCF Growth Rate among Medical Devices & Instruments companies is 18.00, based on 584 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kestra Medical Technologies's current 3-Year FCF Growth Rate of 20.40% is 13.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Kestra Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median 3-Year FCF Growth Rate is 18.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current 3-Year FCF Growth Rate is 20.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current 3-Year FCF Growth Rate of 20.40%. The current 3-Year FCF Growth Rate is 20.40% and 13.3% above the Medical Devices & Instruments industry median of 18.00. Kestra Medical Technologies' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current 3-Year FCF Growth Rate is 20.40% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
12GF Score
Get the complete analysis for KMTS
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMTS has been successfully added to your 
